Treatment of Dizziness by Massotherapy and Traditional Chinese Drugs——A Report of 110 cases

Note: HLY = hyperactivity of the liver-yang, STPMJ = stagnation of turbid phlegm in middle-Jiao, DQB = deficiency of qi and blood, DKE = deficiency of the kidney-essence, OCBS = obstruction of collaterals by blood

Drug Deslgn Based on Chinese Traditional Medicine

There are two new trends in the development of novel Pharmaceuticals. Biotechnology provides a novel approach to rational drug design. At the same time, there has been a growing interest in the use of herbal products. Chinese medical herbs are rich in the natural resources and have been used for thousands years in China. We consider the Chinese medicine system as a natural combinatorial chemi-

PROGRESS OF RESEARCH IN THE PREPARATION OF CHINESE TRADITIONAL AND HERBAL DRUGS WITH ANTICANCER ACTIVITY

Research into anticancer substances madefrom Chinese herbal drugs and their clinicalapplication is gaining international attention bythe medical profession of the more than 20analogues of camptothecine isolated from Camp-totheca tree in China, most exhibited anticanceractivity. Among them, 10-hydroxycamptothe-cine has a wide anticancer spectrum and is lesstoxic. In suspension, it exhibits some therapeu-tic effects on primary hepatic cancer, gastriccarcinoma, cancer of the urinary bladder andleukemia.

Brain organoids are new tool for drug screening of neurological diseases

At the level of in vitro drug screening,the development of a phenotypic analysis system with highcontent screening at the core provides a strong platform to support high-throughput drug screening.There are few systematic reports on brain organoids,as a new three-dimensional in vitro model,in terms of model stability,key phenotypic fingerprint,and drug screening schemes,and particula rly rega rding the development of screening strategies for massive numbers of traditional Chinese medicine monomers.This paper reviews the development of brain organoids and the advantages of brain organoids over induced neurons or cells in simulated diseases.The paper also highlights the prospects from model stability,induction criteria of brain organoids,and the screening schemes of brain organoids based on the characteristics of brain organoids and the application and development of a high-content screening system.

Highlight of Publications on Chinese Traditional and Herbal Drugs in 2008

Chinese Traditional and Herbal Drugs (CTHD),also known as Zhongcaoyao,was founded in January 1970. There are 40 volumes,near 500 issues including supplemental to 2009 have been published. In 1992 it was awarded national core publication published in Chinese and kept the title to date via four times reevaluations at 1996,2000, 2004,and 2008. As one of

New Progress in Modern Research on Chinese Herbal Medicines Published in Chinese Traditional and Herbal Drugs in 2010:Annual Highlights and Comments

As a series of and continuous publication,the papers published on Chinese Traditional and Herbal Drugs in 2010 were selectively and briefly highlighted to reflect the new progress on modern research of Chinese herbal medicines.Within 617 articles,chemical constituents(127),pharmaceutics and technology(149),pharmacological studies and clinical observation,and medicinal materials are still major categories.Some comments have also been personally provided.

Introduction of Chinese Traditional and Herbal Drugs

The journal published monthly since January 1970 is an academic and technical journal sponsored by Chinese Pharmaceutical Association and Tianjin Institute of Pharmaceutical Research (TIPR). The journal which has a long history of 40-years offers the columns of research papers brief reports, reviews, dissertation, and special treatises to report the recent achievements of our basic study, production quality control, and clinic application on traditional Chinese medicine and Chinese materia medica.

Introduction of Chinese Traditional and Herbal Drugs

The journal, published monthly since January 1970, is an academic and technical journal sponsored by Chinese Pharmaceutical Association and Tianjin

Effect of Traditional Chinese Medicine on Survival and Quality of Life in Patients with Esophageal Carcinoma after Esophagectomy

Objective： To explore the effect and possible mechanism of traditional Chinese medicine （TCM） on survival and quality of life （QOL） in patients with esophageal carcinoma after esophagectomy. Methods： Adopting prospective controlled method of study, the authors had 128 post-esophagectomy patients, hospitalized from February 2001 to February 2002, randomly divided into 3 groups： the TCM group, treated with TCM drugs alone; the chemotherapy group, with chemotherapy alone applied; and the synthetic group, treated with chemotherapy combined with Chinese medicine. Their survival rate and QOL were compared. Results： In the TOM group, the chemotherapy group and the synthetic group, the respective 3-year relapse and remote metastasis rate were 71.4%, 76.7%, 53.4%, respectively （X2 =6.53, P^0.05） ; the 1-year survival rate 42.9%, 46.5%, 72.1% ; 2-year survival rate 28.6%, 27.9%, 55.8%, and 3-year survival rate 26.2%, 23. 1%, 37. 2%, respectively. And the QOL improving rate was 69. 0%, 37. 2%, 58.1%, respectively, all showing significant difference among them （X^2 =6. 10, all P〈0.05）. Moreover, immune function was increased in the TCM and the synthetic groups. Conclusion： Integrative Chinese and Western medicinal treatment was the beneficial choice for post-operational patients with esophageal carcinoma. However, long time use of simple Chinese medicine was also advisable, especially for those in poverty.

Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma

Background Transarterial chemoembolization （TACE） is the most widely used primary treatment for unresectable hepatocellular carcinoma （HCC） due to its survival benefit, though its clinical effect is still far from satisfactory. Jiedufang （JDF） granule preparation is a commonly used Chinese herbal medicine formula for HCC. The aim of this study was to evaluate the effect of combined therapy with TACE and JDF granule preparation in treatment of unresectable HCC on survival. Methods A retrospective study of TACE was performed in 165 patients with unresectable HCC who were admitted between January 2002 and December 2007 in Changhai Hospital, Shanghai, China. Of the 165 patients, 80 patients （study group） received combined therapy consisting of TACE and a long-term maintenance treatment with oral JDF granule preparation, and the remaining 85 patients （control group） received TACE alone. The survival rates of both groups were calculated by the Kaplan-Meier method. Factors possibly affecting survival were assessed by multivariate analysis in the Cox proportional hazard model, such as maximum tumor size, number of lesions, portal vein invasion, and etc. Results The median overall survival was 9.2 months （95% CI： 6.94-11.46） in the study group versus 5.87 months （95% CI： 4.21-7.52） in the control group. In the study group,survival rates of the 1-, 2- and 3-year follow-up were 41.2%, 18.4%, and 9.6%, respectively. Significant independent prognostic factors identified by the Cox regression analysis were as follows： serum hepatitis B surface antigen （HBsAg） （P=0.014）, maximum tumor size （P=0.027）, number of lesions （P 〈0.001）, portal vein invasion （P 〈0.001）, and the therapy model （P=-0.006）. Conclusion Combination therapy of TACE and JDF granule preparation may significantly prolong survival of patients with unresectable HCC.

Retrospective Analysis and Summary on Efficacy of Jianpi Shengxue Tablet in the Treatment of Iron Deficiency Anemia

[Objectives]The research aimed to make a retrospective analysis and summary on the efficacy of Jianpi Shengxue Tablet in the treatment of iron deficiency anemia.[Methods]A total of 200 patients with iron deficiency anemia who were treated at outpatient in Tongzhou District of Dongzhimen Hospital of Beijing University of Chinese Medicine from January 1,2017 to October 30,2020 were selected as the research objects.All these patients were given treatment with Jianpi Shengxue Tablet for the first time.Results of blood routine examination,serum iron concentration,total iron binding capacity and ferritin were compared before and after treatment at different dates.Subjective symptoms and adverse reactions were also described.Jianpi Shengxue Tablet was given orally after meals,3 tablets each time,3 times a day.[Results]Hemoglobin level was(83.58±15.81)g/L(M±SD,n=200)before treatment,and(103.40±12.60)g/L(n=74)after 2 week's treatment,with a 24.3%increase(P=0.0047).Hemoglobin concentration was(111.9±19.4)g/L(n=47)at the 4th week after treatment,which was near normality;(126.0±9.49)g/L(n=30)at the 6th week with complete normality and(130.7±7.95)g/L(n=23)at the 8th week.MCV,MCH and MCHC increased gradually after treatment.Serum total iron biding capacity decreased,while serum iron and ferritin increased gradually,and the three indexes were significantly different at the 4th week after treatment as compared with those before treatment(P﹤0.01).Subjective symptoms were improved in the 1st week from starting treatment among all the cases.The adverse events were mainly gastrointestinal irritation,occurring in 7/200 cases(3.5%).[Conclusions]Jianpi Shengxue Tablet is quite effective and safe in the treatment of iron deficiency anemia,with rapid comprehensive improvement of anemia-related symptoms and increase of hemoglobin and red blood cell parameters.

Information

The journal, Chinese Traditional and Herbal Drugs (CTHD), published monthly since January 1970 is an academic and technical journal sponsored by Chinese Pharmaceutical Association and Tianjin Institute of Pharmaceutical Research (TIPR). The journal which has a